Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Nat Biomed Eng. 2021 Nov 1;5(11):1320–1335. doi: 10.1038/s41551-021-00805-x

Fig.8 |. Treatment of BML-210, CUDC-101 or GSK-LSD1 promotes the cytotoxicity of autologous CD8+ T cells in patient-derived organoids (PDOs).

Fig.8 |

a, Characterization of PDOs from six breast cancer patients using H&E staining and immunofluorescence analysis. EpCAM+ and α-SMA+ cells represent breast cancer epithelial cells and cancer-associated fibroblast cells, respectively. b, Schematic illustration of the co-culture of PDOs and autologous tumour-infiltrating CD8+ T cells. c, Death proportions of tumour cells in the PDOs treated with control, BML-201, CUDC-210 or GSK-LSD1 after co-culture with autologous CD8+ T cells. Two-way ANOVA test was used for statistical analysis and data from two biologically parallel experiments are presented as mean ± SD. ***, p < 0.001; ****, p < 0.0001; ns, no significance.